Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake

Texto completo
Autor(es):
Mostrar menos -
Espada, Caroline R. [1] ; Magalhaes, Rubens M. [2] ; Cruz, Mario C. [3] ; Machado, Paulo R. [4] ; Schriefer, Albert [5] ; Carvalho, Edgar M. [4, 6] ; Hornillos, Valentin [7, 8] ; Alves, Joao M. [1] ; Cruz, Angela K. [2] ; Coelho, Adriano C. [9, 1] ; Uliana, Silvia R. B. [1]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular & Mol & Bioagentes Patogen, Ribeirao Preto - Brazil
[3] Univ Sao Paulo, CEFAP, Ctr Facilidades Apoio & Pesquisa, Sao Paulo, SP - Brazil
[4] Univ Fed Bahia, HUPES, Serv Imunol, Salvador, BA - Brazil
[5] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA - Brazil
[6] Fiocruz Bahia, Ctr Pesquisas Goncalo Moniz, Salvador, BA - Brazil
[7] Univ Seville, Dept Quim Organ, Seville - Spain
[8] Ctr Innovac Quim Avanzada ORFEO CINQA, Seville - Spain
[9] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, Campinas, SP - Brazil
Número total de Afiliações: 9
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 11, n. SI, p. 139-147, DEC 2019.
Citações Web of Science: 0
Resumo

In Brazil, cutaneous leishmaniasis is caused predominantly by L. (V.) braziliensis. The few therapeutic drugs available exhibit several limitations, mainly related to drug toxicity and reduced efficacy in some regions. Miltefosine (MF), the only oral drug available for leishmaniasis treatment, is not widely available and has not yet been approved for human use in Brazil. Our group previously reported the existence of differential susceptibility among L. (V.) braziliensis clinical isolates. In this work, we further characterized three of these isolates of L. (V.) braziliensis chosen because they exhibited the lowest and the highest MF half maximal inhibitory concentrations and were therefore considered less tolerant or more tolerant, respectively. Uptake of MF, and also of phosphocholine, were found to be significantly different in more tolerant parasites compared to the less sensitive isolate, which raised the hypothesis of differences in the MF transport complex Miltefosine Transporter (MT)Ros3. Although some polymorphisms in those genes were found, they did not correlate with the drug susceptibility phenotype. Drug efflux and compartmentalization were similar in the isolates tested, and amphotericin B susceptibility was retained in MF tolerant parasites, suggesting that increased fitness was also not the basis of observed differences. Transcriptomic analysis revealed that Ros3 mRNA levels were upregulated in the sensitive strain compared to the tolerant ones. Increased mRNA abundance in more tolerant isolates was validated by quantitative PCR. Our results suggest that differential gene expression of the MT transporter complex is the basis of the differential susceptibility in these unelected, naturally occurring parasites. (AU)

Processo FAPESP: 15/09080-2 - Avaliação de candidatos a fármacos para o tratamento de leishmaniose no Brasil
Beneficiário:Silvia Reni Bortolin Uliana
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 12/14629-5 - Mecanismos de ação e resistência à Miltefosina Leishmania spp.
Beneficiário:Adriano Cappellazzo Coelho
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 16/23405-4 - Suscetibilidade à miltefosina em isolados clínicos de Leishmania (Viannia) braziliensis: caracterização fenotípica e investigação das bases envolvidas na redução de suscetibilidade ao fármaco
Beneficiário:Caroline Ricce Espada
Linha de fomento: Bolsas no Brasil - Doutorado Direto
Processo FAPESP: 11/20484-7 - Tamoxifeno no tratamento de leishmaniose: avaliação de eficácia em esquemas de combinação de drogas e estudo do mecanismo de ação
Beneficiário:Silvia Reni Bortolin Uliana
Linha de fomento: Auxílio à Pesquisa - Regular